coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Pennines PCN, Rochdale (LAD) · Health Inequalities Profile

    PCN U55161 · NHS Greater Manchester Integrated Care Board · 6 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    37,770

    Registered population

    59.7% aged 18–64

    21.4%

    Aged 65+

    ICB 14.9% · England 17.9%

    18.5%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~6,833

    Core20 residents (est.)

    Resident basis; registered basis ~6,514 · see page 3

    7,088

    Hypertension register

    +9.37% in 3 yrs · England +5.60%

    447

    SMI register

    14.3% of Rochdale (LAD)'s

    1,021

    COPD register

    Reviews +10.66% in 3 yrs

    Forecast to 2030

    8,686

    Hypertension patients, 2030

    +1,598 on today

    69.6%

    QRISK ≥20% on statins, 2030

    +2.39pp over 3 yrs

    5.5%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -8.5%
    Learning disability prevalence fell over three years.

    QOF learning disability prevalence (216 patients) changed -8.5% over 2023 to 2025 (England +5.4%, Rochdale (LAD) -15.8%), which may reflect coding differences requiring audit.

    13
    Three-year changes trail England across 13 measures.

    Across 25 measures, 13 trail England's 2023 to 2025 change, including QRISK ≥ 20% lipid therapy (+3.8% vs England +6.2% and Rochdale (LAD) +4.9%).

    78.8%
    Cervical screening coverage exceeds all comparators.

    Cervical screening at ages 25-49 reaches 78.8% (Rochdale (LAD) 68.8%, NHS Greater Manchester Integrated Care Board 65.9%, England 66.8%), rising +2.7% (England -1.0%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Patients aged 65+ comprise 21.4% of registrations, exceeding borough and national rates

    Across six constituent practices and 37,770 registered patients, 21.4% (8,076 patients) are aged 65+, above Rochdale (14.7%), NHS Greater Manchester Integrated Care Board (14.9%) and England (17.9%). Those aged 0-17 comprise 18.9% (7,133), below Rochdale (23.5%), the ICB (21.8%) and England (19.6%); 59.7% (22,561) are aged 18-64 (Rochdale 61.8%, ICB 63.3%, England 62.7%). Recorded Gypsy or Irish Traveller and Roma groups are 0.0% (Rochdale 0.1%, ICB 0.1%, England 0.1% and 0.2%). Projected list growth to 2030 is 1.1% (Rochdale 1.4%, ICB 1.6%, England 2.3%). Observation periods are unstated and projection methodology is unverified.

    Age profile

    0–1718.9%
    18–6459.7%
    65+21.4%

    65+: ICB 14.9%, England 17.9%

    Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Rochdale LA)2,3002,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.1%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)61.8%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Rochdale LA)1,0881,0219552024/25
    Falls deaths, all ages, per 100,000 (Rochdale LA)19.018.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 deprivation is below borough levels but spans 10.1 pp across practices

    PENNINES PCN has an average IMD decile of 4.4 and a Core20 registered share of 18.5%, below Rochdale (48.0%), NHS Greater Manchester Integrated Care Board (40.7%) and England (21.0%). The weighted practice share is 17.3%, an unverified 1.23 pp discrepancy. Across practices, Core20 shares span a 10.1 pp range. Milnrow Village Practice records 12.1%, while Littleborough Group Practice records 22.2%. Targeting balances concentration and volume: Littleborough Group Practice has 1,890 estimated Core20 patients, whereas Stonefield Street Surgery has 1,317 estimated Core20 patients despite a 15.0% share.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Littleborough22.2% · 1,890 patients
    Trinity19.7% · 837 patients
    Village Medical19.4% · 815 patients
    Pennine17.4% · 657 patients
    Stonefield Street15.0% · 1,317 patients
    Milnrow Village12.1% · 998 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    447

    SMI register

    1.19% recorded prevalence

    216

    Learning disability register

    0.57% recorded prevalence

    18

    Care homes, 446 beds

    In the PCN catchment

    9.7%

    Provide unpaid care

    Rochdale (LAD), Census 2021

    Inclusion-health registers record 447 severe mental illness patients (1.2% vs England 1.0%) and 216 with learning disabilities (0.6% vs England 0.6%), with 18 catchment care homes (446 beds). Borough benchmarks show 9.7% unpaid carers and 2 rough sleepers in 2025; these are local authority figures, not PCN headcounts.

    Severe mental illness: physical health checks

    SMI prevalence is 1.2% (England 1.0%). Recorded checks show 85.8% for blood pressure and 83.1% for BMI, where three-year progress (+2.0 pp) trailed England (+5.1 pp). Slower recording growth may leave cardiovascular risks unaddressed across the 447 patients.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,088

    Hypertension register

    +9.37%

    Register growth, 3 yrs

    Rochdale (LAD) +6.17% · England +5.60%

    +0.57pp

    BP control, under 80

    ≤140/90 · +1.18pp aged 80+

    +1,598

    More patients by 2030

    Forecast 8,686 (22.48%)

    Hypertension case-finding and control

    Hypertension recorded prevalence is 18.8% (7,088 patients), above Rochdale (15.6%), NHS Greater Manchester Integrated Care Board (14.4%) and England (15.2%), with the register expanding +9.4% over 2023 to 2025 (England +5.6%). Recent blood pressure recording reaches 90.3% (England 90.0%) and treatment to target is 71.2% (England 70.3%). However, three-year progress in blood pressure control for patients under 80 rose +0.8%, trailing Rochdale (+3.1%) and England (+3.2%), with current control at 67.7% (England 67.8%). Slower control gains could reflect titration delays, though unverified locally. With blood pressure control progress trailing national gains despite high recording, prioritising medication titration and home blood pressure monitoring could improve outcomes across this large registered caseload.

    Lipids and statins

    For patients with QRISK ≥ 20%, 64.5% receive lipid-lowering therapy, above England (63.6%) but behind Rochdale (68.3%), while diabetes statin coverage is 72.6% (England 73.2%, Rochdale 76.6%). Lower therapy rates than borough peers indicate an opportunity to audit high-risk QRISK and diabetes registers to expand primary cardiovascular prevention.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202658,580£2.30£1.94£1.86£134,734
    Cardiovascular (all), 202580,738£4.57£3.15£3.33£368,973

    In 2026, the PCN prescribed 58,580 lipid-modifying items at £2.30 per item, compared with Rochdale (£2.08), NHS Greater Manchester Integrated Care Board (£1.94), and England (£1.86), spending £25,775 more than at England's unit cost. Higher unit costs than comparators highlight an opportunity for a formulary review to optimise statin choices without compromising clinical control.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    +9.89%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    +1.39%

    Asthma prevalence, PCN 3-yr % change

    Asthma prevalence is 7.8% (2,766 patients; England 6.6%) and COPD is 2.7% (1,021 patients; England 1.9%). Annual reviews reached 68.5% in asthma (England 65.7%) and 80.5% in COPD (England 76.4%), leaving about 870 asthma patients unreviewed. Asthma prescribing in ages 5–19 is 1,979 items per 1,000 (England 1,488), while second-hand smoke recording for ages 6–19 (78.0%, 255 patients) trails Rochdale (81.6%). This combination could reflect unreviewed maintenance or environmental exposure, though not locally verified.

    Cancer register and children's immunisation

    Cancer prevalence is 4.6% (1,733 patients; England 3.8%). In childhood immunisation (Q1 2025/26), 6-in-1 coverage at 12 months is 95.8% (calculated England 91.0%), exceeding the 95.0% target. At age 5, 4-in-1 pre-school booster coverage is 90.2%, below the 95.0% target by 4.8 pp, while MMR dose 1 (96.7%) exceeds dose 2 (94.6%) by 2.1 pp. Lower booster uptake may leave children under-protected before school entry.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months95.8%

    England 91.0%

    6-in-1 complete primary course at 24 months93.8%

    England 92.2%

    MMR dose 1 at 24 months93.8%

    England 88.3%

    MMR dose 2 at age 594.6%

    England 82.8%

    4-in-1 pre-school booster at age 590.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of cancers with a known stage in NHS Greater Manchester ICB (6,491 of 11,679) were diagnosed at stage 1 or 2, above England (55.3%) but below the 75.0% national ambition by 19.4 pp, leaving a gap of about 2,270 extra early-stage diagnoses. Known stage was recorded for 70.8% of registrations (11,679 of 16,492); these figures describe the ICB rather than PCN performance. Pennines PCN records 1,733 cancer patients (4.6% prevalence vs England 3.8%) and screening coverage of 78.8% in cervical and 78.0% in breast.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In July 2026 (provisional), Northern Care Alliance NHS Foundation Trust achieved 78.6% on the 62-day cancer standard, below the 85.0% standard by 6.4 pp, trailing Calderdale and Huddersfield NHS Foundation Trust (87.7%) but ahead of Tameside and Glossop Integrated Care NHS Foundation Trust (76.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). Its 28-day faster diagnosis reached 75.2% (standard 75.0%), and 31-day treatment reached 94.5% (standard 96.0%). Six-week diagnostic waits were 5.1% for MRI and 4.1% for CT. These acute trust metrics describe provider performance, not PCN performance.

    Pathways within standard (%)Northern Care AllianceTameside and Glossop Integrated CareCalderdale and HuddersfieldGreater Manchester ICBEngland
    28-day faster diagnosis (75%)75.2082.4877.9879.5379.32
    31-day treatment (96%)94.5496.2597.8996.4992.50
    62-day referral to treatment (85%)78.6576.7787.6675.7371.16
    Diagnostic waits over 6 weeks (%)Northern Care AllianceTameside and Glossop Integrated CareCalderdale and HuddersfieldEngland
    MRI5.090.006.2921.40
    CT4.100.180.599.92
    Echocardiography31.480.0044.1228.48
    Colonoscopy40.041.510.5630.83
    Gastroscopy36.485.450.2929.02
    All 15 DM01 tests15.710.8011.4823.14
    Community services activityRochdale residentsGreater Manchester ICB
    Care contacts60,250573,310
    Referrals9,45594,470
    Patients with a contact19,345183,535

    Community services (residents of Rochdale), Jun 2026 (provisional). In June 2026 (provisional), Community Services Dataset records show 24,650 of 60,250 community contacts for Rochdale residents were with adults aged 65 and over, representing 40.9% of total activity. These borough-level figures describe local authority residents' activity rather than PCN performance.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Good practice experience exceeds England despite a 22.7 percentage point phone access spread

    In 2025/26, practice clinical QOF achievement reached 95.3% to 100.0% against England's 97.1%. However, vaccination and immunisation domain achievement spans 49.0 pp, from 41.9% at Littleborough Group Practice to 90.9% at The Village Medical Ctr. against England's 55.2%. Personalised care adjustments in this domain ranged from 0.7% to 4.6%.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Milnrow Village11012.192.0%81.6%95.4%
    Village Medical10419.469.4%62.4%94.0%
    Trinity12319.788.2%76.0%92.6%
    Stonefield Street9415.072.1%80.8%90.4%
    Pennine Surgery11017.491.2%71.8%90.3%
    Littleborough11922.272.9%83.0%87.3%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNRochdale (LAD)AssetPCNRochdale (LAD)
    Care homes (catchment)18 (446 beds)n/aSchools (catchment)41n/a
    Children's centres217Places of worship27116
    Libraries512Primary schools (LA maintained)738
    Primary academies726Special schoolsn/a2

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review and prescribing recall

    Across 2,766 asthma patients (7.8% vs England 6.6%), 68.5% had a review in the last 12 months (Rochdale (LAD) 66.2%, England 65.7%), leaving 871 (about 870) unreviewed. For discussion, the PCN could run a single-template asthma recall combining inhaler checks and second-hand smoke recording across high-share and high-volume Core20 practices. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Learning disability register validation and recall

    The learning disability register holds 216 patients (0.6% vs Rochdale (LAD) 0.7%, England 0.6%), falling 8.5% over 2023 to 2025 (England +5.4%), giving a +6 to +32 modelled gap. For discussion, practices could audit diagnostic codes against historical records and social-care lists where sharing exists, alongside accessible annual review invitations. Low cost, quick to run.

    Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.

    Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.

    Option 3

    Hypertension titration and lipid therapy review

    Across 7,088 hypertension patients (18.8% vs England 15.2%), under-80 BP control is 67.7% (+0.8% over 2023 to 2025 vs +3.2%); 2026 lipid-modifying items cost £2.30 (England £1.86). Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Learning disability register audit (p2)Learning disability: QOF prevalence75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Two-track Core20 outreach targeting (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Annual SMI physical health review (p4)Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs)MHIS · From Harm to HopePCN
    Hypertension titration protocol (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall outreach (p6)4-in-1 pre-school booster (DTaP/IPV) coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening uptake outreach (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Review appointment booking pathways (p9)GPPS last request led to a booked appointment10YHP, hospital to communityPractice
    Option 1 · Structured asthma review and prescribing recall (p12)Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Learning disability register validation and recall (p12)Learning disability register · Learning disability: QOF prevalence · Registered population75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Option 3 · Hypertension titration and lipid therapy review (p12)Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP readingCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15